Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- AMLX
- Price
- 5.05
- Stock movement down
- -0.05 (-0.98%)
- Company name
- Amylyx Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 450.30M
- Ent value
- 432.97M
- Price/Sales
- 2.29
- Price/Book
- 2.29
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 206.06%
- 3 year return
- -32.18%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-08-27
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
AMLX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2.29 |
| Price to Book | 2.29 |
| EV to Sales | 2.20 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 89.17M |
| EPS (TTM) | -3.81 |
| FCF per share (TTM) | -1.40 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 196.49M |
| Gross profit (TTM) | 61.97M |
| Operating income (TTM) | -249.29M |
| Net income (TTM) | -259.47M |
| EPS (TTM) | -3.81 |
| EPS (1y forward) | -1.52 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 31.54% |
| Operating margin (TTM) | -126.88% |
| Profit margin (TTM) | -132.05% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 71.84M |
| Net receivables | 1.73M |
| Total current assets | 245.26M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 250.71M |
| Accounts payable | 1.49M |
| Short/Current long term debt | 2.57M |
| Total current liabilities | 53.91M |
| Total liabilities | 54.51M |
| Shareholder's equity | 196.20M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -95.09M |
| Capital expenditures (TTM) | 531.00K |
| Free cash flow (TTM) | -95.62M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -132.24% |
| Return on Assets | -103.49% |
| Return on Invested Capital | -130.93% |
| Cash Return on Invested Capital | -48.25% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 5.15 |
| Daily high | 5.15 |
| Daily low | 4.86 |
| Daily Volume | 1.40M |
| All-time high | 40.93 |
| 1y analyst estimate | 11.63 |
| Beta | -0.45 |
| EPS (TTM) | -3.81 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 6 Nov 2025 |
Downside potential
Loading...
Downside potential data
| AMLX | S&P500 | |
| Current price drop from All-time high | -87.66% | -3.04% |
| Highest price drop | -96.04% | -56.47% |
| Date of highest drop | 18 Jun 2024 | 9 Mar 2009 |
| Avg drop from high | -56.60% | -11.04% |
| Avg time to new high | 33 days | 12 days |
| Max time to new high | 601 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
450.30M
Marketcap category
Small-cap
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Employees
123
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page